Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Akero’s 96-Week Fibrosis Data Sparkle In MASH

Mar 05 2024

• By Joseph Haas

Liver health — Akero shows significant fibrosis reduction in 96-week Phase IIb data • Source: Shutterstock

Additional Topics

Clinical Trials Drug Approval Standards Business Strategies Research & Development Liver & Hepatic Metabolic Disorders BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.